How Virtual Trials Support Patient-Centricity: In this digital age, virtual trials may very well become the norm at some point in the future, but there are many questions to answer before this can become a reality.
Authors: Geetesh Shrivastava, Associate Director of Clinical Monitoring; Jennifer Dennis-Wall, PhD, Lead Scientific Writer
Back in August, […]
When recruiting patients with hard-to-enroll indications, such as rare diseases, it is sometimes necessary to […]
The liver does many important things in the body, such as filtering of the blood and […]
Earlier this year, a few of us attended DIA 2018 to represent Biorasi. While there, we […]
Last week, one of our resident experts in ophthalmology, Ignacio Handal, gave a training for some […]
When people think about women’s health, especially during the month of October, they may think […]
Many clinical trials are initiated by a pharmaceutical company in order to generate data to submit […]
The CKD community has set some lofty goals for the coming years. There are hopes to enroll 30% of patients with CKD in a clinical trial by 2030. This is important to create a more substantial research base for CKD.
Global studies are notoriously complicated with language barriers, time zone differences, and oft-contradictory regulations. These business challenges are exacerbated, not only working with multiple, but unique cultures. Biorasi encountered this scenario when we were brought in to rescue a complex clinical trial being run in the US and Japan.
